NovaMedica is a modern Russian pharmaceutical company that was created in 2012 to drive breakthrough developments in the field of pharmaceutics in Russia. As a portfolio company of RUSNANO JSC, NovaMedica aims to bring intellectual property rights to innovative medical products and technologies to Russia. They specialize in the development and commercialization of new drugs and devices for the Russian and CIS markets and boast a GMP production facility.

NovaMedica's impressive portfolio includes drugs for the treatment of oncological and orphan diseases, including epilepsy, as well as innovative technologies for the diagnostics of infectious diseases. They also own IP rights to innovative solutions in the RusnanoMedInvest venture fund's portfolio in Russia and the CIS. The company has made significant strides in research and development with the opening of the R&D Center NovaMedica Innotech.

This state-of-the-art facility is equipped with cutting-edge technological capabilities and holds a manufacturing license and GMP certificate issued by the Russian Ministry of Industry and Trade. NovaMedica is actively working towards creating a range of their own products, from formulation development to clinical trials, state registration, and market launch. They have already achieved marketing authorizations for some of their products, with their first own R&D product becoming part of Bayer's portfolio through a partnership agreement.

Furthermore, NovaMedica is dedicated to growing its CNS product portfolio through both in-house developments and licensing deals with various partners. They have established a robust infrastructure for the promotion and sales of pharmaceutical products, with AstraZeneca as their partner in this endeavor. The company prides itself on its team of top managers who bring years of experience in successful pharmaceutical project implementation.

Many of their team leaders have received recognition by consistently making it to the TOP 1000 Russian Managers List. This expertise ensures that NovaMedica maintains a high standard of quality and innovation in everything they do. NovaMedica's unparalleled dedication to advancing healthcare in Russia is demonstrated by their significant contributions to the production of one of the world's most sought-after drugs for migraine therapy, as well as their commitment to localizing popular anti-migraine drugs in Russia.

With their focus on innovation, collaboration, and high-quality pharmaceutical solutions, NovaMedica continues to make a significant impact in the field of pharmaceutics, driving progress and providing hope for patients and healthcare professionals in Russia and the CIS